UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Statistical methods in recent HIV noninferiority trials: reanalysis of 11 trials

PloS one, 2011-09, Vol.6 (9), p.e22871-e22871

2011

Volltextzugriff (PDF)

Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients

PloS one, 2012-05, Vol.7 (5), p.e36673-e36673

2012

Volltextzugriff (PDF)

Choice of treatment-effect measures when noninferiority margins originally defined in absolute difference translated into relative difference influenced the results of clinical trials

Journal of clinical epidemiology, 2018-04, Vol.96, p.63-72

2018

Volltextzugriff (PDF)

Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen

PloS one, 2011-09, Vol.6 (9), p.e24798

2011

Volltextzugriff (PDF)

Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks

PloS one, 2012-07, Vol.7 (7), p.e41390-e41390

2012

Volltextzugriff (PDF)

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc

PloS one, 2015-06, Vol.10 (6), p.e0127816-e0127816

2015

Volltextzugriff (PDF)

Scoring methods for building genotypic scores: an application to didanosine resistance in a large derivation set

PloS one, 2013-03, Vol.8 (3), p.e59014

2013

Volltextzugriff (PDF)

A polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activity

PloS one, 2013-10, Vol.8 (10), p.e74078-e74078

2013

Volltextzugriff (PDF)

Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes

PloS one, 2013-01, Vol.8 (1), p.e54381-e54381

2013

Volltextzugriff (PDF)

The Use of the Restricted Mean Survival Time as a Treatment Measure in HIV/AIDS Clinical Trial: Reanalysis of the ACTG A5257 Trial

Journal of acquired immune deficiency syndromes (1999), 2019-05, Vol.81 (1), p.44-51

2019

Volltextzugriff (PDF)

Addition of Etravirine Does Not Enhance the Initial Decline of HIV-1 RNA in Treatment-Experienced Patients Receiving Raltegravir

Journal of acquired immune deficiency syndromes (1999), 2017-08, Vol.75 (4), p.448-454

2017

Volltextzugriff (PDF)

Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients

AIDS (London), 2008-01, Vol.22 (3), p.385-393

2008

Volltextzugriff (PDF)

Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy

Journal of antimicrobial chemotherapy, 2014-03, Vol.69 (3), p.753-756

2014

Volltextzugriff (PDF)

Does first-line antiretroviral regimen impact risk for chronic kidney disease whatever the risk group?

AIDS (London), 2016-06, Vol.30 (9), p.1433-1438

2016

Volltextzugriff (PDF)

Factors Associated With Virological Failure in HIV-1-Infected Patients Receiving Darunavir/Ritonavir Monotherapy

The Journal of infectious diseases, 2011-10, Vol.204 (8), p.1211-1216

2011

Volltextzugriff (PDF)

Predictive strength of Jonckheere's test for trend: an application to genotypic scores in HIV infection

Statistics in medicine, 2007-10, Vol.26 (24), p.4441-4454

2007

Volltextzugriff (PDF)

Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study

Journal of acquired immune deficiency syndromes (1999), 2012-12, Vol.61 (5), p.557-564

2012

Volltextzugriff (PDF)

Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies

Clinical infectious diseases, 2018-11, Vol.67 (12), p.1883-1889

2018

Volltextzugriff (PDF)

Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1

Journal of medical virology, 2015-02, Vol.87 (2), p.187-191

2015

Volltextzugriff (PDF)

Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy

Journal of antimicrobial chemotherapy, 2012-06, Vol.67 (6), p.1470-1474

2012

Volltextzugriff (PDF)

Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen

Journal of antimicrobial chemotherapy, 2016-05, Vol.71 (5), p.1352-1360

2016

Volltextzugriff (PDF)

Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial

Journal of antimicrobial chemotherapy, 2010-05, Vol.65 (5), p.1005-1007

2010

Volltextzugriff (PDF)

Risk factors for raltegravir resistance development in clinical practice

Journal of antimicrobial chemotherapy, 2012-10, Vol.67 (10), p.2494-2500

2012

Volltextzugriff (PDF)

Natural evolution of CD4+ cell count in patients with CD4 >350 or >500cells/mm3 at the time of diagnosis according to HIV-1 coreceptor tropism

Journal of medical virology, 2012-12, Vol.84 (12), p.1853

2012

Volltextzugriff (PDF)

Switching to darunavir/ritonavir 800/100mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1

Journal of medical virology, 2013-01, Vol.85 (1), p.8-15

2013

Volltextzugriff (PDF)

1 – 25 von 34

Suche als RSS-Feed

Aktive Filter

SpracheFranzösisch

ThemaHiv

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(34)

Sprache

Englisch
(34)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Statistical methods in recent HIV noninferiority trials: reanalysis of 11 trials

Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients

Choice of treatment-effect measures when noninferiority margins originally defined in absolute difference translated into relative difference influenced the results of clinical trials

Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen

Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc

Scoring methods for building genotypic scores: an application to didanosine resistance in a large derivation set

A polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activity

Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes

The Use of the Restricted Mean Survival Time as a Treatment Measure in HIV/AIDS Clinical Trial: Reanalysis of the ACTG A5257 Trial

Addition of Etravirine Does Not Enhance the Initial Decline of HIV-1 RNA in Treatment-Experienced Patients Receiving Raltegravir

Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients

Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy

Does first-line antiretroviral regimen impact risk for chronic kidney disease whatever the risk group?

Factors Associated With Virological Failure in HIV-1-Infected Patients Receiving Darunavir/Ritonavir Monotherapy

Predictive strength of Jonckheere's test for trend: an application to genotypic scores in HIV infection

Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study

Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies

Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1

Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy

Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen

Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial

Risk factors for raltegravir resistance development in clinical practice

Natural evolution of CD4+ cell count in patients with CD4 >350 or >500cells/mm3 at the time of diagnosis according to HIV-1 coreceptor tropism

Switching to darunavir/ritonavir 800/100mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1

Aktive Filter

Suchergebnisse filtern